These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 1967976

  • 1. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK, McGinty JF, Hong JS.
    Brain Res; 1990 Jan 15; 507(1):57-64. PubMed ID: 1967976
    [Abstract] [Full Text] [Related]

  • 2. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
    Jiang HK, Wang JY.
    Chin J Physiol; 1991 Jan 15; 34(4):413-25. PubMed ID: 1687937
    [Abstract] [Full Text] [Related]

  • 3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 15; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 4. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG, Walters JR.
    Brain Res; 1987 Mar 10; 405(2):234-46. PubMed ID: 2952219
    [Abstract] [Full Text] [Related]

  • 5. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
    Bronstein DM, Ye H, Pennypacker KR, Hudson PM, Hong JS.
    Brain Res Mol Brain Res; 1994 May 10; 23(3):191-203. PubMed ID: 7914658
    [Abstract] [Full Text] [Related]

  • 6. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
    Engber TM, Boldry RC, Kuo S, Chase TN.
    Brain Res; 1992 May 29; 581(2):261-8. PubMed ID: 1356580
    [Abstract] [Full Text] [Related]

  • 7. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
    Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR.
    Science; 1990 Dec 07; 250(4986):1429-32. PubMed ID: 2147780
    [Abstract] [Full Text] [Related]

  • 8. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ, Marshall JF.
    Behav Brain Res; 1990 May 28; 38(3):233-42. PubMed ID: 1973041
    [Abstract] [Full Text] [Related]

  • 9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 28; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 10. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT, Wachtel SR, Galloway MP, White FJ.
    J Neurosci; 1990 Jul 28; 10(7):2318-29. PubMed ID: 1973947
    [Abstract] [Full Text] [Related]

  • 11. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE, Wooten GF.
    Brain Res Mol Brain Res; 1992 Jan 28; 12(1-3):111-9. PubMed ID: 1312196
    [Abstract] [Full Text] [Related]

  • 12. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum.
    Li SJ, Jiang HK, Stachowiak MS, Hudson PM, Owyang V, Nanry K, Tilson HA, Hong JS.
    Brain Res Mol Brain Res; 1990 Aug 28; 8(3):219-25. PubMed ID: 1977070
    [Abstract] [Full Text] [Related]

  • 13. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH, Starr MS.
    Neuroscience; 1987 Dec 28; 23(3):1001-10. PubMed ID: 2963970
    [Abstract] [Full Text] [Related]

  • 14. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Dec 28; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 15. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE, Yates TM.
    Neuroscience; 1999 Dec 28; 94(2):505-14. PubMed ID: 10579212
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM, Marin C, Susel Z, Chase TN.
    Eur J Pharmacol; 1993 Jun 04; 236(3):385-93. PubMed ID: 8102970
    [Abstract] [Full Text] [Related]

  • 17. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
    Sivam SP, Breese GR, Krause JE, Napier TC, Mueller RA, Hong JS.
    J Neurochem; 1987 Nov 04; 49(5):1623-33. PubMed ID: 2889804
    [Abstract] [Full Text] [Related]

  • 18. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX, Walters JR.
    J Pharmacol Exp Ther; 1994 Dec 04; 271(3):1434-43. PubMed ID: 7996456
    [Abstract] [Full Text] [Related]

  • 19. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
    Turski WA, Cavalheiro EA, Ikonomidou C, Bortolotto ZA, Klockgether T, Turski L.
    Synapse; 1990 Dec 04; 5(2):113-9. PubMed ID: 2137942
    [Abstract] [Full Text] [Related]

  • 20. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK, Manzino L, Heikkila RE.
    J Pharmacol Exp Ther; 1988 Oct 04; 247(1):180-5. PubMed ID: 2971797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.